ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 176 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2016. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $7,727,000 | -66.8% | 114,000 | -65.6% | 0.12% | -68.8% |
| Q4 2016 | $23,288,000 | +35.8% | 331,220 | +37.0% | 0.37% | +25.7% |
| Q3 2016 | $17,148,000 | +7045.0% | 241,720 | +4816.0% | 0.30% | +5820.0% |
| Q2 2016 | $240,000 | -71.4% | 4,917 | -62.8% | 0.01% | -68.8% |
| Q1 2016 | $838,000 | -96.4% | 13,232 | -93.7% | 0.02% | -96.2% |
| Q4 2015 | $23,558,000 | -17.3% | 210,000 | -29.0% | 0.43% | -26.2% |
| Q3 2015 | $28,496,000 | +6.2% | 295,879 | +12.9% | 0.58% | +11.8% |
| Q2 2015 | $26,832,000 | +32.8% | 262,061 | -19.5% | 0.52% | +35.1% |
| Q1 2015 | $20,212,000 | – | 325,528 | – | 0.38% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |